TORONTO, Jan. 29 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced its financial and operational results for the fourth quarter and fiscal year, ended November 30, 2007.
"Fiscal 2007 was a critical year in our development, highlighted by the
significant advancement we made with the pre-IND programs for our lead drug
candidates, our CD44 Cancer Stem Cell Program, our Trop-2 Signal
Transduction Program, our CD59 Complement Inhibitor Program and our CD9
Cancer Stem Cell Program. The majority of our programs target cancer stem
cells, an area that cancer researchers are particularly excited about as
cancer stem cells have been implicated as the key cells responsible for the
growth and spread of cancer," said Dr. David Young, President and CEO.
"Building on this momentum, fiscal 2008 will be a pivotal year for us as we
transition from a pre-clinical to a clinical company with the mission of
moving one or more of our lead products into human clinical trials."
CD44 Cancer Stem Cell Program
- Announced positive findings demonstrating no dose-limiting toxic
effects of ARIUS' lead therapeutic, ARH460-16-2, at doses up to
95 mg/kg in a dose-ranging pilot toxicology study in a non-human
- Achieved significant and potent tumor growth inhibitory activity in
in vivo animal models of breast, prostate, liver, and AML cancers.
- Engaged the manufacturer Avid Bioservices to produce ARIUS' lead
anti-CD44 MAb under Current Good Manufacturing Practices ("cGMP") for
human clinical trials. Cell line producing the humanized anti-CD44
antibody was successfully transferred to Avid.
- Presented key data at AACR, ASCO, ASCO's Breast Cancer Symposium,
- Met with FDA to discuss plans
|SOURCE ARIUS Research Inc.|
Copyright©2008 PR Newswire.
All rights reserved